In situ mass spectrometry imaging reveals heterogeneous glycogen stores in human normal and cancerous tissues
Lyndsay E A Young,Lindsey R Conroy,Harrison A Clarke,Tara R Hawkinson,Kayli E Bolton,William C Sanders,Josephine E Chang,Madison B Webb,Warren J Alilain,Craig W Vander Kooi,Richard R Drake,Douglas A Andres,Tom C Badgett,Lars M Wagner,Derek B Allison,Ramon C Sun,Matthew S Gentry
DOI: https://doi.org/10.15252/emmm.202216029
2022-09-10
EMBO Molecular Medicine
Abstract:Development of a MALDI‐based assay for the spatial quantification of microenvironmental glycogen and glycogen biochemical architecture. Hyperphosphorylated glycogen was discovered in human Ewing sarcoma. Targeting tumor‐specific glycogen may be a potential therapeutic approach for Ewing sarcoma. Glycogen dysregulation is a hallmark of aging, and aberrant glycogen drives metabolic reprogramming and pathogenesis in multiple diseases. However, glycogen heterogeneity in healthy and diseased tissues remains largely unknown. Herein, we describe a method to define spatial glycogen architecture in mouse and human tissues using matrix‐assisted laser desorption/ionization mass spectrometry imaging. This assay provides robust and sensitive spatial glycogen quantification and architecture characterization in the brain, liver, kidney, testis, lung, bladder, and even the bone. Armed with this tool, we interrogated glycogen spatial distribution and architecture in different types of human cancers. We demonstrate that glycogen stores and architecture are heterogeneous among diseases. Additionally, we observe unique hyperphosphorylated glycogen accumulation in Ewing sarcoma, a pediatric bone cancer. Using preclinical models, we correct glycogen hyperphosphorylation in Ewing sarcoma through genetic and pharmacological interventions that ablate in vivo tumor growth, demonstrating the clinical therapeutic potential of targeting glycogen in Ewing sarcoma.
medicine, research & experimental